Related Experiment Video
Updated: Jan 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
The investigation and treatment of renal bone disease
Insights
Neutron activation analysis monitored skeletal calcium in hemodialysis patients. Magnesium and oral calcium reduced calcium loss, while a vitamin D analogue increased bone calcium, potentially treating azotemic osteodystrophy.
Area of Science:
- Nephrology
- Biochemistry
- Nuclear Medicine
Background:
- Maintenance hemodialysis patients often experience progressive skeletal calcium loss.
- Azotemic osteodystrophy is a common complication in patients with chronic kidney disease.
Purpose of the Study:
- To monitor skeletal calcium changes in hemodialysis patients.
- To evaluate the efficacy of magnesium therapy, oral calcium supplements, and a vitamin D analogue in preserving or increasing bone calcium content.
Main Methods:
- Neutron activation analysis was employed to measure skeletal calcium levels in the hand.
- Patients received either supplementary magnesium, oral calcium, or 1-alpha-hydroxycholecalciferol.
Main Results:
- Supplementary magnesium therapy reduced skeletal calcium loss in some patients.
- Oral calcium supplements decreased skeletal calcium losses in all patients studied.
- 1-alpha-hydroxycholecalciferol significantly increased bone calcium content in three patients.
Conclusions:
- Magnesium and oral calcium show potential in mitigating bone loss during hemodialysis.
- 1-alpha-hydroxycholecalciferol may be a safe and effective treatment for azotemic osteodystrophy in hemodialysis patients.
Abstract:
Neutron activation analysis of a hand has been used to monitor changes in skeletal calcium content of patients undergoing maintenance hemodialysis. Assessed by this technic supplementary magnesium therapy was of value of reducing the progressive losses of skeletal calcium in a proportion of the patients receiving maintenance hemodialysis. Oral calcium supplements produced a decrease in the skeletal calcium losses of all the patients studied. 1-alpha-hydroxycholecalciferol, a potent vitamin D analogue, caused a significant increase in the calcium content of bone in three patients receiving maintenance hemodialysis; it may prove to be a safe and effective form of therapy for azotemic osteodystrophy.
Related Concept Videos
Bone Remodeling
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Urinary Tract Calculi III: Medical Management

